NCT01790100View on ClinicalTrials.gov

A Phase 2a, Dose-Ranging Study to Evaluate the Safety, Pharmacokinetics and Efficacy of VX-135 With Ribavirin in Treatment-Naïve Subjects With Chronic Hepatitis C

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

February 28, 2013

Primary Completion Date

June 30, 2014

Study Completion Date

June 30, 2014

Conditions
Chronic Hepatitis C
Interventions
DRUG

VX-135

12 weeks of VX-135

DRUG

Ribavirin

12 weeks of ribavirin

Trial Locations (1)

Unknown

Arensia, Republican Clinical Hospital, Chisinau

Sponsors
All Listed Sponsors
collaborator

Vertex Pharmaceuticals Incorporated

INDUSTRY

lead

Alios Biopharma Inc.

INDUSTRY

NCT01790100 - A Phase 2a, Dose-Ranging Study to Evaluate the Safety, Pharmacokinetics and Efficacy of VX-135 With Ribavirin in Treatment-Naïve Subjects With Chronic Hepatitis C | Biotech Hunter | Biotech Hunter